Advertisement
Singapore markets closed
  • Straits Times Index

    3,176.51
    -11.15 (-0.35%)
     
  • Nikkei

    37,068.35
    -1,011.35 (-2.66%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     
  • Bitcoin USD

    64,448.99
    +1,733.98 (+2.76%)
     
  • CMC Crypto 200

    1,384.40
    +71.78 (+5.47%)
     
  • S&P 500

    4,979.64
    -31.48 (-0.63%)
     
  • Dow

    37,976.83
    +201.45 (+0.53%)
     
  • Nasdaq

    15,347.65
    -253.85 (-1.63%)
     
  • Gold

    2,408.00
    +10.00 (+0.42%)
     
  • Crude Oil

    83.14
    +0.41 (+0.50%)
     
  • 10-Yr Bond

    4.6250
    -0.0220 (-0.47%)
     
  • FTSE Bursa Malaysia

    1,547.57
    +2.81 (+0.18%)
     
  • Jakarta Composite Index

    7,087.32
    -79.50 (-1.11%)
     
  • PSE Index

    6,443.00
    -80.19 (-1.23%)
     

What Nektar Therapeutics’ Valuation Trend Indicates

What Nektar Therapeutics’ Valuation Trend Indicates

In October, ten analysts are covering Nektar Therapeutics (NKTR) stock. Eight of them have given the stock a “buy” or higher rating, and two have given it a “hold.” The mean rating for the stock is 1.8 with a target price of $89.38, implying an upside potential of 82.1% over its closing price of $49.08 on October 15.